CAS 72496-41-4

Pirarubicina

Descrição:

Pirarubicina, com o número CAS 72496-41-4, é um antibiótico antraciclínico que é utilizado principalmente como agente antineoplásico na terapia do câncer. É estruturalmente relacionado à doxorrubicina e exibe mecanismos de ação semelhantes, principalmente intercalando-se no DNA, inibindo assim a síntese de DNA e RNA, o que leva à morte celular. Pirarubicina é particularmente eficaz contra vários tipos de câncer, incluindo câncer de mama e leucemia. Seu perfil farmacológico inclui um nível moderado a alto de citotoxicidade, e é frequentemente administrado por via intravenosa. O medicamento é conhecido por seus potenciais efeitos colaterais, que podem incluir cardiotoxicidade, mielossupressão e distúrbios gastrointestinais. Devido à sua estrutura química, Pirarubicina também pode gerar espécies reativas de oxigênio, contribuindo para seus efeitos anticancerígenos. O composto é tipicamente utilizado em combinação com outros agentes quimioterápicos para aumentar a eficácia terapêutica enquanto gerencia a resistência. Assim como com todos os agentes quimioterápicos, o monitoramento cuidadoso dos pacientes é essencial para mitigar efeitos adversos e otimizar os resultados do tratamento.

Fórmula: C₃₂H₃₇NO₁₂

InChI: InChI=1/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19?,21+,22-,31+,32-/m0/s1

Chave InChI: InChIKey=KMSKQZKKOZQFFG-YXRRJAAWSA-N

SMILES: O([C@@H]1C2=C(C(O)=C3C(=C2O)C(=O)C=4C(C3=O)=CC=CC4OC)C[C@](C(CO)=O)(O)C1)[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5

Sinónimos:

• (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-4-O-[(2S)-tetrahydro-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranoside
• (2''R)-4'-O-Tetrahydropyranyladriamycin
• (2′′R)-4′-O-Tetrahydropyranyladriamycin
• (2′′R)-4′-O-Tetrahydropyranyldoxorubicin
• (3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranoside
• (8S,10S)-10-((3-Amino-2,3,6-trideoxy-4-O-(2R-tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
• (8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
• 1609Rb
• 4'-O-Tetrahydropyranyladriamycin
• 4'-O-Tetrahydropyranyldoxorubicin
• 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
• 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[8α,10α(S*)]]-
• 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
• 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
• Pinorubicin
• Pirarubicin Hydrochloride
• Pirarubicin [INN:JAN]
• Pirarubicina
• Pirarubicina [Spanish]
• Pirarubicine
• Pirarubicine [French]
• Pirarubicinum
• Pirarubicinum [Latin]
• THP-adriamycin
• Therarubicin
• (8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
• 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
• 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
• 5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[8α,10α(S*)]]-
• (8S)-10α-[[3-Amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8β-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
• l)-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hy
• (7S,9S)-7-((2R,4S,5S,6S)-4-amino-6-methyl-5-((R)-tetrahydro-2H-pyran-2-yloxy)-tetrahydro-2H-pyran-2-yloxy)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
• 5,12-naphthacenedione,10-((3-amino-2,3,6-trideoxy-4-o-(tetrahydro-2h-pyran-2-y
• (8s-cis)-droxyacetyl)-1-methoxy
• (8S)-10-[(2S,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxy-oxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione
• 5,12-Naphthacenedione, 10-3-amino-2,3,6-trideoxy-4-O-(2R)-tetrahydro-2H-pyran-2-yl-.alpha.-L-lyxo-hexopyranosyloxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
• THP-ADM
• Pirarubicin(THP-AdriaMycin)
• THEPRUBICIN
• Therarubiein
• Pirarubicin(BICINS)
• Pirabucin
• PIRARUBICIN
• (8S,10S)-10-[(2S,4S,5S,6S)-4-Amino-6-methyl-5-[(2S)-oxan-2-yl]oxy-oxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione
• (8S,10S)-10α-[[3-Amino-4-O-(tetrahydro-2H-pyran-2-yl)-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8β-hydroxyacetyl-1-methoxy-5,12-naphthacenedione

(8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

CAS: 72496-41-4

Fórmula: C₃₂H₃₇NO₁₂

Pureza: 97%

Cor e Forma: Solid

Peso molecular: 627.6357

Ref: IN-DA0065SG

Pirarubicin

CAS: 72496-41-4

Pirarubicin

Pureza: ≥95%

Peso molecular: 627.64g/mol

Ref: 54-BUP10616

(8S,10S)-10-(((2R,4S,5S,6S)-4-Amino-6-Methyl-5-(((R)-Tetrahydro-2H-Pyran-2-Yl)Oxy)Tetrahydro-2H-Pyran-2-Yl)Oxy)-6,8,11-Trihydroxy-8-(2-Hydroxyacetyl)-1-Methoxy-7,8,9,10-Tetrahydrotetracene-5,12-Dione

CAS: 72496-41-4

(8S,10S)-10-(((2R,4S,5S,6S)-4-Amino-6-Methyl-5-(((R)-Tetrahydro-2H-Pyran-2-Yl)Oxy)Tetrahydro-2H-Pyran-2-Yl)Oxy)-6,8,11-Trihydroxy-8-(2-Hydroxyacetyl)-1-Methoxy-7,8,9,10-Tetrahydrotetracene-5,12-Dione

Pureza: 98%

Peso molecular: 627.64g/mol

Ref: 54-OR1023344

Pirarubicin

CAS: 72496-41-4

Pirarubicin (Theprubicin), an anthracycline antibiotic, inhibits DNA/RNA synthesis and is used as an antineoplastic.

Fórmula: C₃₂H₃₇NO₁₂

Pureza: 97.80% - 99.15%

Cor e Forma: Red Crystalline Powder

Peso molecular: 627.64

Ref: TM-T6628

Pirarubicin

CAS: 72496-41-4

Fórmula: C₃₂H₃₇NO₁₂

Pureza: ≥ 95%

Cor e Forma: Red to orange powder

Peso molecular: 627.64

Ref: 7W-GA1643

Pirarubicin

CAS: 72496-41-4

Antibiotic of anthracycline class; DNA synthesis inhibitor

Fórmula: C₃₂H₃₇NO₁₂

Pureza: Min. 95%

Cor e Forma: Powder

Peso molecular: 627.64 g/mol

Ref: 3D-FP27079

Pirarubicin

Produto Controlado

CAS: 72496-41-4

Applications Structural analog of Doxorubicin. Antineoplastic.
References Umezawa, H., et al.: J. Antibiot., 32, 1082 (1979), Majima, H., et al.: Biomed. Pharmacother., 41, 237 (1987), Miller, A.A., et al.: Cancer Res., 47, 1461 (1987), Fallik, D., et al.: Ann. Ocol., 14, 856 (2003),

Fórmula: C₃₂H₃₇NO₁₂

Cor e Forma: Neat

Peso molecular: 627.64

Ref: TR-P501500